No connection

Search Results

ACON vs HCTI

ACON
Aclarion, Inc.
BEARISH
Price
$3.33
Market Cap
$3.5M
Sector
Healthcare
AI Confidence
92%
HCTI
Healthcare Triangle, Inc.
BEARISH
Price
$2.40
Market Cap
$2.8M
Sector
Healthcare
AI Confidence
95%

Valuation

P/E Ratio
ACON
--
HCTI
--
Forward P/E
ACON
-0.24
HCTI
-0.08
P/B Ratio
ACON
0.16
HCTI
0.14
P/S Ratio
ACON
52.03
HCTI
0.21
EV/EBITDA
ACON
1.38
HCTI
-1.29

Profitability

Gross Margin
ACON
-7.83%
HCTI
13.12%
Operating Margin
ACON
-9666.16%
HCTI
-74.26%
Profit Margin
ACON
0.0%
HCTI
-48.84%
ROE
ACON
-97.72%
HCTI
-183.0%
ROA
ACON
-52.37%
HCTI
-39.27%

Growth

Revenue Growth
ACON
31.5%
HCTI
44.6%
Earnings Growth
ACON
--
HCTI
--

Financial Health

Debt/Equity
ACON
--
HCTI
0.18
Current Ratio
ACON
17.01
HCTI
2.03
Quick Ratio
ACON
16.31
HCTI
1.94

Dividends

Dividend Yield
ACON
--
HCTI
--
Payout Ratio
ACON
0.0%
HCTI
0.0%

AI Verdict

ACON BEARISH

ACON's deterministic health scores are severely compromised: the Piotroski F-Score of 1/9 signals extreme financial distress, and the absence of an Altman Z-Score (with negative profitability and liquidity anomalies) raises serious bankruptcy concerns. Despite a 31.5% YoY revenue growth, the company exhibits catastrophic profitability—negative gross, operating, and ROE margins—indicating fundamental operational failure. The stock trades at a price/sales of 52.03, vastly exceeding peers and suggesting extreme overvaluation relative to earnings. Analysts' target price of $23.00 is not supported by fundamentals, and insider activity remains neutral with no recent trades. The 5-year price decline of 100% underscores deep investor skepticism.

Strengths
31.5% year-over-year revenue growth indicates top-line expansion
High current and quick ratios (17.01 and 16.31) suggest strong short-term liquidity
Recent 1-month price increase (+22.9%) shows short-term momentum
Risks
Piotroski F-Score of 1/9 indicates severe financial deterioration and poor operational health
Negative operating margin (-9666.16%) and ROE (-97.72%) reflect systemic profitability collapse
Price/Sales of 52.03 is unsustainable and far exceeds peer averages (avg: ~185.39 P/E, but negative margins suggest no valid comparison)
HCTI BEARISH

HCTI presents a classic value trap scenario, characterized by a stable Piotroski F-Score of 4/9 but catastrophic price action and fundamental decay. While the company shows strong top-line revenue growth of 44.6%, it is coupled with a disastrous ROE of -183% and an operating margin of -74.26%. The extreme discrepancy between the 52-week high ($7470) and current price ($2.40) indicates a total collapse in investor confidence or a massive corporate restructuring. Despite low debt and a healthy current ratio, the lack of profitability and negative earnings surprises make this a high-risk speculative asset.

Strengths
Strong YoY revenue growth of 44.60%
Low Debt/Equity ratio of 0.18
Healthy liquidity with a Current Ratio of 2.03
Risks
Catastrophic price performance (-99.9% 1Y change)
Severe negative profitability (Profit Margin -48.84%)
Extreme equity erosion (ROE -183%)

Compare Another Pair

ACON vs HCTI: Head-to-Head Comparison

This page compares Aclarion, Inc. (ACON) and Healthcare Triangle, Inc. (HCTI) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile